Yalonda Howze - Feb 16, 2022 Form 4 Insider Report for Codiak BioSciences, Inc. (CDAKQ)

Role
Officer title: Executive Vice President, Chief Legal and Compliance Officer and Corporate Secretary
Signature
/s/ Yalonda Howze
Stock symbol
CDAKQ
Transactions as of
Feb 16, 2022
Transactions value $
$0
Form type
4
Date filed
2/18/2022, 03:05 PM
Previous filing
Jan 21, 2022
Next filing
Feb 21, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CDAKQ Stock Option (Right to Buy) Award $0 +13K $0.00 13K Feb 16, 2022 Common Stock 13K $5.21 Direct F1
transaction CDAKQ Restricted Stock Units Award $0 +19.4K $0.00 19.4K Feb 16, 2022 Common Stock 19.4K Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of this option shall vest and become exercisable on February 16, 2023, with the remainder vesting in 12 equal quarterly installments thereafter.
F2 Each restricted stock unit represents a contingent right to receive one share of common stock.
F3 On February 16, 2022, the reporting person was granted 19,425 restricted stock units, vesting in four equal installments every six months beginning on the six month anniversary of the grant date.

Remarks:

Officer title: Executive Vice President, Chief Legal and Compliance Officer and Corporate Secretary